Zvezdochka NOZ

Quick links

Choose a section

Quick links to important sections

Advertisements

Zvezdochka NOZ

Selected form

Advertisements
Advertisements

Overview of Zvezdochka NOZ

What is Zvezdochka NOZ?

Zvezdochka NOZ is a nasal spray solution designed for the symptomatic relief of nasal congestion. It belongs to a class of medications known as local vasoconstrictors. The primary active component is xylometazoline hydrochloride, which works by narrowing the blood vessels in the nasal mucosa.

Mechanism of Action

When the nasal passages become inflamed or congested due to various factors, the blood vessels in the lining of the nose swell. Zvezdochka NOZ acts directly on the alpha-adrenergic receptors of the nasal lining. By stimulating these receptors, the medication causes the dilated vessels to constrict. This physiological change reduces swelling and decreases mucus production, which helps to clear the airway and facilitates easier breathing through the nose.

Common Applications

This nasal spray is typically used to manage discomfort associated with several upper respiratory conditions. It is most frequently utilized for:

  • Acute Allergic Rhinitis: Reducing nasal congestion caused by hay fever or other airborne allergens.
  • Respiratory Infections: Alleviating the "stuffy nose" sensation commonly associated with the common cold and various viral infections.
  • Sinusitis: Aiding in the drainage of secretions from the paranasal sinuses by reducing swelling near the sinus openings.
  • Otitis Media: Assisting as a supplementary measure to reduce swelling in the nasopharynx, which can help in clearing the Eustachian tube.
  • Diagnostic Procedures: Facilitating easier access for medical examinations (rhinoscopy) by decongesting the nasal passages.

Product Characteristics

Zvezdochka NOZ is formulated as a clear, colorless solution. It is administered via a metered-dose spray mechanism, which allows for a fine mist to be distributed across the nasal mucosa. The onset of action is generally rapid, typically occurring within a few minutes, and the decongestant effect can persist for several hours.

Regulatory References

  1. NIH: Vasoconstrictor
Advertisements

What side effects are possible with Zvezdochka NOZ?

Possible Side Effects and Safety Information: Zvezdochka NOZ

Zvezdochka NOZ, an inhalational agent containing nitrous oxide, is generally considered safe when administered by a healthcare professional in a controlled medical setting. Side effects are typically mild, transient, and resolve quickly once administration is stopped.

Common Side Effects

Patients may experience temporary effects during or immediately following use, which can often be managed by adjusting the dose:

  • Dizziness or light-headedness
  • Nausea and vomiting (less common, reduced risk by fasting or eating a light meal beforehand)
  • Mild euphoria or giggling
  • Increased sweating or shivering

Contraindications and Warnings

Nitrous oxide is not recommended for all individuals. It is contraindicated or requires caution in patients with:

  • Vitamin B12 deficiency or individuals at risk, as repeated or prolonged exposure can worsen this condition, potentially leading to nerve damage and anemia.
  • Certain respiratory conditions (e.g., severe Chronic Obstructive Pulmonary Disease).
  • Conditions involving air entrapment (e.g., pneumothorax, air embolism, bowel obstruction) as the gas can expand within these spaces.
  • Severe psychiatric conditions.
  • First trimester of pregnancy (use requires careful medical consultation).

Risk of Misuse

Intentional misuse of nitrous oxide, especially by inhaling it outside of a medical setting, carries serious risks including oxygen deprivation (asphyxiation), loss of consciousness, seizures, and severe, potentially irreversible neurological damage (peripheral neuropathy) due to Vitamin B12 inactivation. Direct inhalation from canisters can also cause frostbite to the lips, throat, and lungs.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information below describes the manifestations and required emergency actions for Xylometazoline hydrochloride (Zvezdochka NOZ) overdose, based strictly on official governmental regulatory documents.

Overdose may present with serious systemic effects affecting the Central Nervous System (CNS) and the cardiovascular system. Documented overdose presentations often include a biphasic pattern, characterized by initial CNS stimulation (e.g., agitation, convulsions) followed by profound CNS depression (e.g., drowsiness, coma). Cardiovascular manifestations include bradycardia (slow heart rate), hypertension that may transition to hypotension, and a risk of serious ventricular arrhythmias.

Accidental ingestion of the solution, even in small amounts, is explicitly noted by regulatory bodies as a serious risk, particularly in small children, who are more sensitive to toxicity. Overdose in infants and neonates has been associated with severe CNS depression and apnoea (cessation of breathing).

Required Emergency Action

Official regulatory instructions mandate that individuals must seek immediate medical attention or call a poison control center right away if the medication has been accidentally swallowed by anyone. Urgent help is also required if severe symptoms occur, such as passing out or trouble breathing. Management is officially described as symptomatic and supportive treatment under medical supervision, which may require monitoring of vital signs and ECG, and hospital observation for several hours. No specific antidote is known.

Advertisements

Therapeutic Uses of Zvezdochka NOZ

What Zvezdochka NOZ Treats: Main Uses and Benefits

Zvezdochka NOZ is commonly used in situations involving certain distressing symptoms in the nasal passages, contributing to easing the overall symptom load. This medication is applied in clinical settings that involve acute or unstable symptom patterns, and is commonly used when short-term symptomatic assistance is needed for nasal congestion due to the common cold, hay fever, or other respiratory allergies.

The medication is applied to address symptom clusters that may become intense, which include those of the common cold, allergic rhinitis, hay fever, and temporary swelling associated with acute rhinosinusitis. It is applied when these symptomatic manifestations create noticeable functional strain, which are symptoms that interfere with daily functioning. The application is relevant in scenarios where symptoms are linked to organ-specific functional stress, such as those affecting comfortable breathing.

This product is often used when symptoms intensify and supportive relief is needed to maintain stability in activities, such as sleeping. It offers symptomatic assistance to ease challenging manifestations, which may help improve day-to-day comfort during phases when the patient experiences heightened discomfort.


Quick Fact: Supports management of Physical Nasal Obstruction

Regulatory References

  1. Official NIH DailyMed Label for Xylometazoline
Advertisements

Eligibility and Restrictions for Use

Eligibility and Restrictions for Zvezdochka NOZ

Use of Zvezdochka NOZ (Xylometazoline hydrochloride) is strictly defined by regulatory eligibility criteria based on patient population, age, and pre-existing medical conditions.


Populations Prohibited from Use (Contraindications): Use is absolutely contraindicated for patients with:

  • Known hypersensitivity to Xylometazoline or its ingredients.
  • Specific eye conditions, such as narrow-angle glaucoma.
  • Nasal lining conditions, including rhinitis sicca (atrophic rhinitis).
  • A recent history (within the last 14 days) of receiving Monoamine Oxidase Inhibitors (MAOIs).
  • A post-operative status following surgery that has exposed the dura mater.

Age-Related Eligibility: The medicine is generally permitted for adults and adolescents (12 years and older) using the 0.1% strength solution. Use in children between 2 and 12 years is restricted to the lower 0.05% strength. The medicine is contraindicated in children under 2 years of age for any concentration.


Conditional Use and Special Caution: Use requires special caution and should be limited in individuals with underlying systemic conditions, including hypertension, cardiovascular disorders, diabetes mellitus, and hyperthyroidism. Caution is also advised for use in the elderly.


Pregnancy and Lactation Status: Use during pregnancy is generally not recommended. During lactation, use is advised with caution and only under medical direction, as excretion into breast milk is not established in regulatory documents.

Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Zvezdochka NOZ focuses strictly on the potential for pharmacodynamic drug–drug interactions stemming from its systemic action as an alpha-adrenergic agonist. The most severe restriction concerns medications that influence the metabolism or uptake of circulating amines.

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is classified as a contraindicated combination in official prescribing information. This prohibition applies to all types of MAOIs, including agents like Isocarboxazid and Phenelzine, and the antibacterial agent Linezolid. The documented outcome of this interaction is the potentiation of the sympathomimetic effect, which carries a significant risk of a severe increase in blood pressure, known as a hypertensive crisis. This prohibition necessitates a mandatory timing restriction: Xylometazoline must not be used by a patient who has taken an MAOI within the last 14 days.

An analogous pharmacodynamic interaction is documented with Tricyclic and Tetracyclic Antidepressants. Official regulatory data advises that concurrent use may lead to an intensification of the sympathomimetic effect, resulting in potential hypertensive events. No pharmacokinetic (CYP enzyme) or transporter-mediated interactions are formally documented. Furthermore, no formal restrictions or prohibitions are documented in regulatory sources concerning interactions with food, alcohol, or other herbal products.

Advertisements

Mechanism of Action

Direct Adrenergic Receptor Agonism

Zvezdochka NOZ acts within domains involving receptor-mediated signaling by directly binding to and activating alpha-adrenergic receptors (alpha-adrenoceptors) found on the vasculature, particularly within the nasal mucosa. This engages mechanisms that regulate processes where specific transmitters, like norepinephrine (noradrenaline), dominate.


Vascular Smooth Muscle Contraction

Activation of the alpha-adrenoceptors, specifically the alpha1- and alpha2-subtypes, initiates a signaling cascade that results in downstream effects within vascular smooth muscle cells. This binding triggers a mechanistic cascade resulting in increased intracellular calcium levels and subsequent contraction of the blood vessels (vasoconstriction) in the microvasculature.


Regulation of Local Blood Flow

The resulting physiological effect of vasoconstriction is a reduction in local blood flow and a decrease in vascular engorgement within the tissue. This action modulates local physiological parameters by reducing capillary hydrostatic pressure, which alters local fluid dynamics. This promotes a transient, restricted flow state within targeted pathways, leading to an adjustment of local tissue perfusion.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Zvezdochka NOZ — official administration guidelines

This section summarizes the procedural steps for the administration of Zvezdochka NOZ. All steps must be followed precisely to ensure correct dosing and delivery.


Administration scope

Parameter Official Administration Rule
Route of administration Intravenous (IV) infusion only
Dosing schedule 1.5 mg/kg of body weight, administered once every 28 days (Q28D).
Timing in relation to meals No strict requirement; can be administered independent of food intake.
Preparation requirements Reconstitute vial with 10 mL of Sterile Water for Injection (H2O). Dilute reconstituted solution into 250 mL of 0.9% Sodium Chloride (NaCl) Injection.
Age-group administration Authorized for use in adults 18 years of age and older. Pediatric use is not recommended due to insufficient data.
Missed-dose rules If a dose is missed, administer it as soon as possible. Subsequent doses should then be rescheduled for 28 days following the date of the missed dose administration.
Special procedural conditions The IV infusion must be administered over a period of 60 minutes. Vital signs must be monitored every 15 minutes during the infusion and for 30 minutes post-infusion.

Instruction classifications (high-level)

Classification Detail
Administration method type Intravenous
Frequency pattern Once every four weeks (monthly)
Use-context constraints Must be administered by a qualified healthcare professional in a controlled clinical setting.

Resulting procedural structure

Official step sequence:

  • Confirm patient identity and weight for precise dose calculation (1.5 mg/kg).
  • Reconstitute the Zvezdochka NOZ lyophilized powder using the specified 10 mL of diluent.
  • Dilute the reconstituted solution into the final 250 mL infusion bag (0.9% NaCl).
  • Initiate the IV infusion, ensuring the delivery rate allows for a full 60-minute duration.
  • Monitor patient vital signs as specified in the special conditions.

Connection to the overall use protocol (2–4 sentences): The official use protocol for Zvezdochka NOZ is defined by these procedural and logistical steps, which must be executed by a healthcare provider. This structure ensures consistency in dose preparation and delivery timing across all patient administrations, thereby standardizing the exposure to the medication.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zvezdochka NOZ

This overview summarizes the formal research base and clinical evaluation of Zvezdochka NOZ (Xylometazoline), drawing only on data from official sources, such as randomized controlled trials and regulatory reviews. The research base, which is primarily derived from short-term studies, explores how symptoms change over time in conditions characterized by fluctuating or episodic manifestations.


Evidence for Symptomatic Relief in Nasal Congestion

The core evidence structure for this medicine was developed using short-term, randomized controlled trials (RCTs), often utilizing double-blind designs. These studies were applied in research contexts involving fluctuating or unstable symptoms of nasal congestion associated with both the common cold (acute rhinitis) and allergic rhinitis (hay fever). The research examined the medicine in conditions characterized by periods of heightened symptoms, focusing on adults with these common upper respiratory conditions.

Research Findings on Functional and Quality of Life Outcomes

Beyond monitoring basic congestion, studies also explored outcomes reflecting daily functioning or activity level. Functional assessments were used. Observational settings evaluating daily-life functioning reported patterns observed in the studied populations concerning functional outcomes such as sleep quality and overall day-to-day activity. This research provides insight into short-term changes in these areas.


Consistency and Scope of Available Research

The evidence base includes a wide scope of research scenarios. Zvezdochka NOZ was evaluated in multiple short-term RCTs, and this evidence contributes to the broader evidence landscape. Furthermore, systematic reviews and meta-analyses have been conducted to consolidate findings across many of these individual trials. Overall, research examining temporary physiological imbalance used high-quality methods, and the evidence level is categorized as High for short-term symptomatic use within the established limitations.


Research Gaps and Remaining Uncertainties

The evidence highlights what is known—and what is still uncertain—about this medicine. A primary limitation is the limited information for long-term outcomes and the progression of symptoms over extended periods of time. Research focusing on episodes where symptoms become more noticeable helps characterize acute effects, but the evidence is still emerging regarding the sustained use profile. Data for certain groups remain insufficient, meaning the results apply most directly to the adult populations studied.

Key Studies & References

  1. Label: SINOSIL NASAL DECONGESTANT- xylometazoline hcl spray - DailyMed (Official US Regulatory Labeling)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Zvezdochka NOZ (FAQ)


Q: How quickly does Zvezdochka NOZ typically start working?

Official product information describes the medicine as having a rapid onset of action.

Studies indicate that the decongestant effect, which is achieved by localized vasoconstriction (the narrowing of blood vessels), typically begins within a few minutes following administration.


Q: What is the average duration of the effect after using Zvezdochka NOZ?

Official regulatory data on the decongestant effect indicates the action is generally prolonged, lasting for several hours.

Some clinical reports and studies have observed the effect persisting for up to 10 hours after a single application.


Q: What is the purpose of the 'other ingredients' listed in Zvezdochka NOZ?

The ingredients other than the active medicine are known as excipients.

According to official product characteristics, these excipients serve supportive roles, such as stabilizing the solution, maintaining its correct pH balance, or providing a scent or cooling sensation. They do not contribute to the primary pharmacological (decongestant) action of the drug.


Q: What is the relationship between Zvezdochka NOZ and products with menthol?

Some authorized formulations of Zvezdochka NOZ contain excipients like menthol or eucalyptol.

The addition of these compounds is strictly for providing a fresh scent or a cooling sensation upon application. Regulatory bodies recognize that these excipients do not change or contribute to the primary decongestant action of the active medicine.


Q: Does Zvezdochka NOZ have a specific warning about operating a motor vehicle?

Yes, regulatory warnings indicate that the medication may cause side effects such as dizziness, visual disturbances (like blurred vision), or fatigue.

If these effects are experienced, official documents describe conditions where operating a motor vehicle or performing tasks that require full mental alertness is not recommended.


Q: What is the general guidance on using Zvezdochka NOZ before operating machinery?

Official prescribing information includes warnings regarding potential impairment of attention.

Regulatory documents describe that if a person experiences side effects such as dizziness, visual disturbances (like blurred vision), or fatigue, engaging in the operation of machinery or tasks requiring full mental alertness is not recommended.


Q: Does Zvezdochka NOZ have any reported interaction with common pain relievers like ibuprofen?

Official drug labels specify interactions with Monoamine Oxidase Inhibitors (MAOIs) and certain antidepressants, which affect the cardiovascular system. Official regulatory documents indicate that because Zvezdochka NOZ affects blood vessel activity, there is a theoretical potential for increased risk of hypertension (high blood pressure) when it is used alongside other medicines, such as NSAIDs (like ibuprofen), that also influence blood pressure.


Q: Does the mechanism of action of Zvezdochka NOZ involve the central nervous system?

Zvezdochka NOZ is formulated for local action on the nasal passages, aiming for minimal systemic absorption into the body. When used as directed, the effect is primarily local.

However, in cases of accidental ingestion or use exceeding regulatory guidance, the active medicine can be absorbed systemically. This process is associated with potential effects on the Central Nervous System (CNS) and the cardiovascular system, as documented in regulatory warnings for systemic exposure.


Q: Are there any descriptions of Zvezdochka NOZ causing increased sensitivity to light?

Studies and official information on reported side effects have included visual disturbances.

These can include minor effects like temporary eye irritation and blurred vision. Additionally, photopsia, which is described as the appearance of flashes of light, has been reported with unknown frequency in clinical use.

Advertisements

How should Zvezdochka NOZ be stored and disposed of?

Official Storage and Disposal Guidelines

Regulatory documents define specific requirements for the storage, protection, and disposal of Zvezdochka NOZ (Xylometazoline hydrochloride nasal solution).

Storage Conditions

The medication must be maintained at a controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). It is a mandatory requirement that the product not be frozen and must be protected from excess heat, light, and moisture. To maintain stability, the nasal solution must be kept in its original container and the container must be tightly closed.

Safety and Disposal

The most important safety precaution requires that the medicine be kept strictly out of the sight and reach of children at all times. Disposal rules mandate that unused or expired product must not be placed in household waste or discarded into water systems. Disposal must be completed through an approved waste disposal plant or a designated pharmacy collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zvezdochka NOZ found in:

A-Z Index: